Andrea Miyahira interviews Estefania Labanca about her team’s work, featured in the paper “Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-Derived Xenograft Series.” Dr. Labanca highlights the MD Anderson Prostate Cancer Patient-Derived Xenograft (MDA PCa PDX) Program, a pioneering effort started over 30 years ago by Dr. Navone to model lethal prostate cancer,…
Can’t sign in? Forgot your password? If the address matches an existing account you will receive an email with instructions to reset your password. Can’t…
“I would say, about 10 years ago, there was a real skepticism, a healthy skepticism, I would say, in the beginning. Now that has slowly…
Purpose:Multiple factors are thought to give rise to common, recurrent kidney stone disease, but for monogenic stone disorders a firm diagnosis is possible through genetic…
Zach Klaassen facilitates a conversation on the continuum of care in metastatic hormone-sensitive prostate cancer (mHSPC) with Jason Hafron and Elisabeth Heath. The discussion underscores…
“I think that it is upon us as urologists to try to start to embrace this clinical accomplishment, and that being trying to make our…
Jason Efstathiou discusses the PARTIQoL trial, a randomized phase III study comparing proton beam therapy to IMRT for localized prostate cancer. Dr. Efstathiou discusses the…
In a recent study, mean sensitivity was 85.5% and specificity 87% for detection of clear-cell renal cell carcinoma
Alicia Morgans hosts a discussion with Paul Eber and Brad Somer to explore the collaborative management of metastatic hormone-sensitive prostate cancer cases. They highlight a…
“We found that the new TENACIO pump was able to complete tasks faster and more efficiently compared to the older MS pump,” says Justin Lee,…
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Bone Health Management for Advanced Prostate Cancer – Fred Saad Part…
